Document is current
Any future updates will be listed below
-
Authors
Kojima, Kanako
Ichinose, Kunihiro
Umeda, Masataka
Shimizu, Toshimasa
Sato, Shuntaro
Suzuki, Takahisa
Nakashima, Yoshikazu
Okada, Akitomo
Horai, Yoshiro
Fujikawa, Keita
Aramaki, Toshiyuki
Miyashita, Taiichiro
Furuyama, Masako
Matsuoka, Naoki
Kawakami, Atsushi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (23K07895)
Japan Society for the Promotion of Science (21K20905)
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 19 May 2025
First Online: 29 May 2025
Declarations
:
: This study was performed in accord with the Declaration of Helsinki and was approved by the Investigation and Ethics Committee at Nagasaki University Hospital (approval no. 19102116–6). The patients gave their informed consent to be subjected to the protocol.
: Some of the patients provided written informed consent for the use and publications of their data, and the opt-out strategy was used by the remainder of the patients.
: KI has received speaker honoraria from AbbVie GK, Asahi Kasei Pharma Corporation, AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K. (GSK), Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., and Taisho Pharmaceutical Co., Ltd. MU has received honoraria from AbbVie GK, Asahi Kasei Pharma Corporation, AstraZeneca K.K., and GlaxoSmithKline K.K. (GSK). TS has received honoraria from AstraZeneca K.K. and GlaxoSmithKline K.K. (GSK). AK has received honoraria from AbbVie GK, Asahi Kasei Pharma Corporation, Boehringer Ingelheim, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Pfizer, and Taisho Pharmaceutical Co., Ltd.
